A Biotech That May Boost an Anemic Portfolio

by Sam Collins | February 16, 2012 1:08 am

A Biotech That May Boost an Anemic Portfolio

Celgene Corp. (NASDAQ:CELG[1]) – This company is considered by S&P to have “the brightest growth prospects among large-cap biotech companies.” Its impressive performance was led by its cancer products Revlimid and Vidaza. The company also has a number of other products in the pipeline awaiting FDA approval and is considered by many analysts to be a leader in cancer treatments.

Earnings for 2011 met adjusted estimates of $2.85, and S&P estimates earnings of $4.44 in 2012 and $5.11 in 2013. Gross margins are expected to maintain 93%. Street analysts predict a price target of $93 within 12 months.

The Trade of the Day has followed CELG since July, and recently recommended it on Feb. 3[2] at $74.16.

Technically CELG broke from a compound top on Sept. 20 on heavy volume, then again from a double-top at $69, and again yesterday at $74.50 in spite of a very negative day for the stock market.

These breaks are called “step-up patterns” and mostly occur on stocks in an aggressive bull market. A bullish signal from our internal indicator, the Collins-Bollinger Reversal (CBR) occurred on Jan. 27, and a new stochastic buy was flashed on Feb. 13.

The trading target for CELG is $80 within 30 days and $100-plus longer term.

02 16 12 celg 300x183 A Biotech That May Boost an Anemic Portfolio
Click to Enlarge

chart key A Biotech That May Boost an Anemic Portfolio

sam collins banner 520x64 A Biotech That May Boost an Anemic Portfolio[3]

Endnotes:
  1. CELG: http://studio-5.financialcontent.com/investplace/quote?Symbol=CELG
  2. recommended it on Feb. 3: http://investorplace.com/2012/02/trade-of-the-day-celgene-corp-nasdaqcelg/
  3. [Image]: https://www.facebook.com/investorplace?sk=app_20819510252812

Source URL: http://investorplace.com/2012/02/trade-of-the-day-celgene-corp-nasdaq-celg-2/
Short URL: http://invstplc.com/1fvfJ1B